← Leaderboards
Kevin Finnbar Staveleyo'carroll
Pennsylvania State Univ Hershey Med Ctr
$5,239,458
Attributed
$9,637,990
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,637,990 · 6
VA$0 · 1
By mechanism
R01$8,961,640 · 5
K08$676,350 · 1
I01$0 · 1
Top collaborators
- Guangfu Li16 shared
- Mark Kester5 shared
- Eric T. Kimchi4 shared
- Randy Scott Rector3 shared
Most similar at Pennsylvania State Univ Hershey Med Ctr
Same institution · by research overlap
- Mark Kester$13,621,664
- Eric T. Kimchi$462
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingImmune ResponseTumor AntigensImmunotherapyTumorLiverImmune TolerancePrimary Carcinoma Of The Liver CellsResponseImmuneMolecularPathway InteractionsIn VivoMalignant NeoplasmsGrowthRegulatory T-LymphocyteImmunotherapeutic AgentLiver FibrosisTumor GrowthCancer InitiationMouse ModelTherapeutic EffectCd8-Positive T-LymphocytesTumor Immunity
Grant awards (31)
Targeting KLF2 in macrophages to improve immune checkpoint therapy for hepatocellular cancer$627,562
R01 · FY2025 · CA
Mechanistic studies of gut microbiota-mediated immune activation against hepatocellular cancer$488,308
R01 · FY2025 · CA · contact PI
Mechanistic studies of gut microbiota-mediated immune activation against hepatocellular cancer$474,805
R01 · FY2024 · CA · contact PI
Mechanisms of gut microbiota/metabolite interface-mediated hepatic inflammation$397,590
R01 · FY2024 · DK
Mechanistic studies of gut microbiota-mediated immune activation against hepatocellular cancer$457,731
R01 · FY2023 · CA · contact PI
Mechanisms of gut microbiota/metabolite interface-mediated hepatic inflammation$394,466
R01 · FY2023 · DK
Targeting KLF2 in macrophages to improve immune checkpoint therapy for hepatocellular cancer$330,192
R01 · FY2023 · CA
Targeting KLF2 in macrophages to improve immune checkpoint therapy for hepatocellular cancer$237,330
R01 · FY2023 · CA
Mechanistic studies of gut microbiota-mediated immune activation against hepatocellular cancer$459,004
R01 · FY2022 · CA · contact PI
Mechanisms of gut microbiota/metabolite interface-mediated hepatic inflammation$400,000
R01 · FY2022 · DK
Building a New Therapeutic Paradigm for Hepatocellular Cancer by Dissecting the Interaction between Radiofrequency Ablation, Chemotherapy, and Immunotherapy$0
I01 · FY2022 · VA
Combination of ceramide and immunotherapy in treatment of hepatocellular cancer$553,074
R01 · FY2021 · CA · contact PI
Mechanistic studies of gut microbiota-mediated immune activation against hepatocellular cancer$464,474
R01 · FY2021 · CA · contact PI
Building a New Therapeutic Paradigm for Hepatocellular Cancer by Dissecting the Interaction between Radiofrequency Ablation, Chemotherapy, and Immunotherapy$0
I01 · FY2021 · VA
Combination of ceramide and immunotherapy in treatment of hepatocellular cancer$569,928
R01 · FY2020 · CA · contact PI
Building a New Therapeutic Paradigm for Hepatocellular Cancer by Dissecting the Interaction between Radiofrequency Ablation, Chemotherapy, and Immunotherapy$0
I01 · FY2020 · VA
Combination of ceramide and immunotherapy in treatment of hepatocellular cancer$551,141
R01 · FY2019 · CA · contact PI
Building a New Therapeutic Paradigm for Hepatocellular Cancer by Dissecting the Interaction between Radiofrequency Ablation, Chemotherapy, and Immunotherapy$0
I01 · FY2019 · VA
Combination of ceramide and immunotherapy in treatment of hepatocellular cancer$545,802
R01 · FY2018 · CA · contact PI
Combination of ceramide and immunotherapy in treatment of hepatocellular cancer$531,242
R01 · FY2017 · CA · contact PI
An Orthotopic Murine Model of HCC: Immunotolerance and Prevention$301,525
R01 · FY2016 · CA · contact PI
An Orthotopic Murine Model of HCC: Immunotolerance and Prevention$197,336
R01 · FY2016 · CA · contact PI
An Orthotopic Murine Model of HCC: Immunotolerance and Prevention$106,043
R01 · FY2015 · CA · contact PI
An Orthotopic Murine Model of HCC: Immunotolerance and Prevention$269,129
R01 · FY2014 · CA · contact PI
An Orthotopic Murine Model of HCC: Immunotolerance and Prevention$296,509
R01 · FY2013 · CA · contact PI
An Orthotopic Murine Model of HCC: Immunotolerance and Prevention$308,449
R01 · FY2012 · CA · contact PI
Tumor Antigen Presentation in Mice Developing Cancer$135,270
K08 · FY2008 · CA · contact PI
Tumor Antigen Presentation in Mice Developing Cancer$135,270
K08 · FY2007 · CA · contact PI
Tumor Antigen Presentation in Mice Developing Cancer$135,270
K08 · FY2006 · CA · contact PI
Tumor Antigen Presentation in Mice Developing Cancer$135,270
K08 · FY2005 · CA
Tumor Antigen Presentation in Mice Developing Cancer$135,270
K08 · FY2004 · CA